Princess Ojiaku
From this contributor
Modified bike helmet scans brains of people in motion
A magnetic scanner fitted within an ordinary bicycle helmet may make it easier to visualize autistic children's brains.
Modified bike helmet scans brains of people in motion
Zebrafish show true colors as models for autism sleep studies
Sleeping zebrafish show two patterns of neuronal activity that are analogous to those in people.
Zebrafish show true colors as models for autism sleep studies
For autistic adults, a hospital stay carries high risk of death
Adults with autism are nearly 50 percent more likely to die in the hospital than their typical peers.
For autistic adults, a hospital stay carries high risk of death
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.